BioXcel Therapeutics (BTAI) Tops Q4 EPS by 16c

BioXcel Therapeutics (NASDAQ: BTAI) reported Q4 EPS of ($0.76), $0.16 better than the analyst estimate of ($0.92). Revenue for the quarter came in at $376 thousand versus the consensus estimate of $742.86 thousand.

For earnings history and earnings-related data on BioXcel Therapeutics (BTAI) click here.

You May Also Be Interested In

• Oracle (ORCL) Tops Q1 EPS by 19c, Beats on Revenue; Beats on Cloud Revenue, Offers Q3 EPS Guidance
• RUM Group to raise Northern Data stake to ~98% via share purchase
• Zumiez, Inc. (ZUMZ) Misses Q2 EPS by 6c, Misses on Revenue; Offers Q3 Guidance